CryoCell International Inc (CCEL)vsMerck & Company Inc (MRK)
CCEL
CryoCell International Inc
$4.15
0.00%
HEALTHCARE · Cap: $39.10M
MRK
Merck & Company Inc
$133.72
+0.69%
HEALTHCARE · Cap: $362.27B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 216364% more annual revenue ($67.38B vs $31.13M). MRK leads profitability with a 3.6% profit margin vs -6.3%. CCEL appears more attractively valued with a PEG of 1.34. CCEL earns a higher WallStSmart Score of 47/100 (D+).
CCEL
Hold47
out of 100
Grade: D+
MRK
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+33.5%
Fair Value
$5.02
Current Price
$4.15
$0.87 discount
Margin of Safety
-56.0%
Fair Value
$85.13
Current Price
$133.72
$48.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 129 in profit
Earnings expanding 75.1% YoY
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Strong operational efficiency at 35.2%
Generating 5.5B in free cash flow
Areas to Watch
0.0% revenue growth
Smaller company, higher risk/reward
Operating margin of 0.6%
Distress zone — elevated risk
4.7% revenue growth
ROE of 5.5% — below average capital efficiency
3.6% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : CCEL
The strongest argument for CCEL centers on Return on Equity, EPS Growth, Debt/Equity. PEG of 1.34 suggests the stock is reasonably priced for its growth.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : CCEL
The primary concerns for CCEL are Revenue Growth, Market Cap, Operating Margin.
Bear Case : MRK
The primary concerns for MRK are Revenue Growth, Return on Equity, Profit Margin. A P/E of 148.4x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Key Dynamics to Monitor
CCEL profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.
CCEL carries more volatility with a beta of 0.55 — expect wider price swings.
MRK is growing revenue faster at 4.7% — sustainability is the question.
MRK generates stronger free cash flow (5.5B), providing more financial flexibility.
Bottom Line
CCEL scores higher overall (47/100 vs 42/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CryoCell International Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Cryo-Cell International, Inc. is dedicated to cell processing and cryogenic cell storage with a focus on collecting and preserving umbilical cord blood stem cells for family use. The company is headquartered in Oldsmar, Florida.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?